Latest Conference Coverage

Open-label data of concomitant use of CGRP monoclonal antibodies and receptor antagonists suggest that the agents can be safely and effectively combined in the treatment of migraine.

The reported reasons included wanting to take care of symptoms themselves, concern that migraine will not be taken seriously, and believing migraines are not severe or painful enough to seek care.

Treatment with eptinezumab resulted in reduced burdensome features of headache episodes including severe pain, photophobia, phonophobia, nausea, and limited physical activity.

Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.

Investigators’ analysis of a subset of patients with insufficient response from the CENTURION study suggests that the acute agent from Eli Lilly offers potential in this population.

Treatment with INP104 was associated with high rates of symptoms freedom and may be a promising new acute treatment for patients with migraine.

Experts were in agreement that the criteria should include PTH phenotype, TBI mechanism and TBI comorbidities.

The nasal delivery of dihydroergotamine also showed a lower incidence of nausea than IV-administrated dihydroergotamine.

Rimegepant (Nurtec ODT; Biohaven) had the lowest number needed to treat for sustained pain freedom from migraine.

The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.

Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center, discussed the post-hoc analysis of the ORATORIO trial he and colleagues conducted.

With the AHS 63rd Annual Scientific Meeting set to kick-off virtually on June 3, 2021, Jessica Ailani, MD, FAHS, offered her perspective on what to expect from the presentations and sessions.

The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.

Richard Gershon, PhD, vice chair for research at the Northwestern University Feinberg School of Medicine, discussed the development of the mobile toolbox battery to track cognitive decline.

The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the findings of the post-hoc analysis of the ORATORIO study.

Stephen Rao, PhD, ABPP-Cn, the Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, discussed the development of the MSPT.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the background of the ORATORIO study and the aT2-LV biomarker.

The neurologist at Cleveland Clinic discussed how his data may change clinicians’ perception on the management and prevalence of generalized epilepsy in elders.

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed his work on the ORATORIO study.

A recent paper supported by several presentations at AAN 2021 elucidate areas of migraine care to improve.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed the importance of correcting practice effects to determine performance.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed future ideas for the MANAGE-PD tool to furthering its benefits.

Vineet Punia, MD, MS, shared thoughts on his study from AAN 2021 which characterized generalized epilepsy in older adults and the elderly, and raised questions about its overall prevalence.

Jason Poon, MD, neurologist at University of Utah, discussed his study on diagnostic accuracy in telestroke consultations.